Diabetes Companies

Top Industry Leaders in the Diabetes Market

India Diabetes Key Companies Latest India Diabetes Companies Companies Update

August 2023: Saxagliptin 2.5 mg and 5 mg tablets, which are generic equivalents of Onglyza, a diabetes medication developed by AstraZeneca, were approved by the U.S. Food and Drug Administration (FDA) in August 2023. Aurobindo Pharma and Glenmark Pharmaceuticals, respectively, obtained final FDA approval. In a press release announcing final approval to manufacture and market the bioequivalent and therapeutically equivalent product to the reference-listed drug Onglyza 2.5 mg and 5 mg tablets,

August 2023: A pharmaceutical company, Akums Drugs and Pharmaceuticals Limited, recently introduced a novel formulation in August 2023. This formulation is designed to treat Type-2 Diabetes and is intended for the senior population. The new combination drug, as stated by Akums Drugs and Pharmaceuticals Limited, is intended to provide effective glycemic control for patients with diabetes. The Drug Controller General of India (DCGI) has reportedly approved the treatment, which the company refers to as a "groundbreaking therapy" for the elderly with the disease. Commonly prescribed for the management of diabetes, Vildagliptin SR and Metformin SR will be combined to form the new treatment.

November 2023: USV and Biogenomics jointly declared the introduction of INSUQUICK, a biosimilar insulin aspart, in November 2023. "InsuQuick is a "Make in India" product, having been developed and manufactured entirely with indigenous technology, and having undergone a rigorous clinical program to ensure global quality standards," according to a company statement. It is accessible in Tier I/II cities and all metropolitan areas. Cartridges, vials, and prefilled disposable pens will be offered for Insuquick, providing diabetics with a degree of adaptability.

List of India Diabetes Companies Key companies in the market